Biotechnology & Medical Research

Page 1

CEL-SCI Corp prices $6 mln public offering of common stock and warrants

9:15am EDT

CEL-SCI Corp:Prices underwritten public offering of common stock and warrants at a combined price of $0.76 for aggregate gross proceeds of $6 mln.Offering is expected to close on or about Oct. 24.Intends to use the net proceeds for its Phase III clinical trial, other research and development, and general and administrative expenses.Laidlaw & Company (UK) Ltd. is acting as the sole book-running manager and underwriter for the proposed offering.

Tonix Pharmaceuticals receives IND clearance for TNX-201 in Episodic Tension-Type Headache

8:40am EDT

Tonix Pharmaceuticals Holding Corp:Says the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application to study TNX-201 for the treatment of episodic tension-type headache.Tonix will evaluate the safety, tolerability, and pharmacokinetics of TNX-201 in a healthy volunteers study to be completed before the end of 2014.

BioSpecifics Technologies Corp announces FDA approval of sBLA for XIAFLEX for concurrent treatment of two dupuytren's contracture cords

8:00am EDT

BioSpecifics Technologies Corp:Says U.S. FDA has approved supplemental Biologics License Application (sBLA) submitted by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX.Says XIAFLEX, for treatment of up to two Dupuytren's contracture cords in same hand during single treatment visit.SBLA was based on positive results from global, multicenter Phase 3b MULTICORD ( MUL tiple T reatment I nvestigation of C ollagenase Optimizing R esolution of D upuytren's) trial, together with data from Auxilium's earlier studies.

Aptose Biosciences Inc announces approval for listing on NASDAQ capital market shares

8:00am EDT

Aptose Biosciences Inc:Says that its common shares have been approved for listing on NASDAQ Capital Market under symbol APTO.Begin trading on NASDAQ on or around Oct. 23.Company will retain its listing on Toronto Stock Exchange under symbol APS.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.